Response Biomedical Hits Key Milestone in 3M Collaboration for Infection Prevention
Response Biomedical Corp. announced that it has met a key development milestone as part of the co-development agreement with 3M Health Care announced on November 29, 2004. Under the agreement, 3M Health Care is funding the development of a new rapid, point-of-care microbiology test in the area of infection prevention based on Response Biomedical's RAMP technology. This collaboration is aimed at introducing a product portfolio to improve the outcome of patients entering the hospital system.
"Hospital acquired infections are a tremendous burden on the health care system costing almost US$10 billion per year in the US alone, and result in approximately 12,000 deaths annually," stated Bill Radvak, President & CEO.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.